Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cysal is a German biotechnology company that focuses on the biotechnological production of dipeptides and amino acids using a proprietary fermentation platform. The company utilizes the biopolymer cyanophycin as a precursor to manufacture high-purity dipeptides, such as L-aspartyl-L-arginine, which offer improved solubility and stability. These products are primarily targeted at the cosmetics, animal nutrition, and pharmaceutical industries. By replacing traditional chemical synthesis with sustainable fermentation, Cysal provides an eco-friendly alternative for the production of complex nutritional and active ingredients. The company is a spin-off from the University of Münster and maintains strong ties to academic research in microbiology. Their lead products are already commercially available for use in high-end skincare formulations and specialized animal feed.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cysal.